Based on the results obtained in the current study, endocrine resistance (hsa01522), AGE-RAGE signaling pathway in diabetic complications (hsa04933) and p53 signaling pathway (hsa04115) might be the main signaling pathways of AM in the treatment of acquired hyperlipidemia. This evidence concerns the gene TP53 and hyperlipidemia.